FDA approves four-pack carton for Zepbound single-dose vials
The FDA cleared a four-vial carton for Zepbound, a packaging change that could mean fewer boxes for patients but whose price and availability are not yet disclosed.
The FDA has approved a new packaging option for Zepbound (tirzepatide), allowing the drug's labeling to include single-dose vials in a four-pack carton [1]. The approval covers how the drug is packaged, not any change to the drug itself [1].
The decision came in a letter dated February 7, 2025, approving supplement S-020 to new drug application NDA 217806 [1]. Eli Lilly and Company submitted the supplement on October 15, 2024, under section 505(b) of the Federal Food, Drug, and Cosmetic Act [1]. The FDA said the application was approved "for use as recommended in the enclosed agreed-upon labeling," effective on the date of the letter [1].
According to the letter, the supplement "provides for labeling to include Zepbound single-dose vials in a four-pack vial presentation" [1]. Zepbound is a tirzepatide injection [1]. The letter does not describe the price of the four-pack, the dose strengths of the vials inside, or when the new cartons would reach pharmacies [1].
The FDA also set several deadlines for Lilly. The company must submit its updated labeling in structured product labeling format within 14 days of the letter [1]. Within the same period, it must amend any pending supplemental applications for the same drug application that include labeling changes [1]. Final printed carton and container labels must be submitted no more than 30 days after they are printed, the letter said [1]. The agency added that its approval of those final labels is not required before the labeling is used [1].
The letter was signed by Ramesh Raghavachari, Ph.D., a supervisor in the FDA's Division of Product Quality Assessment IV, part of the Office of Pharmaceutical Quality at the Center for Drug Evaluation and Research [1].
Why it matters for patients
The change is about packaging, not about how the drug works or what it contains. A four-pack carton would put four single-dose vials in one box, which could mean fewer packages for patients to handle, store, or track [1]. The supplement adds a new presentation to the labeling; it does not describe a change to the vials themselves [1].
The approval letter does not address price, insurance coverage, or pharmacy availability [1]. It also does not list which dose strengths will be included in the four-pack or say when the cartons will start shipping [1]. Those details have not been disclosed in the letter.
The letter does not describe any change to how Zepbound is prescribed or used [1].
What happens next
The FDA's letter sets deadlines for the company, not for patients [1]:
- Within 14 days of February 7, 2025, Lilly must submit its updated labeling in structured product labeling format [1].
- Within the same 14 days, it must amend pending supplemental applications for the same drug application that include labeling changes [1].
- Final printed carton and container labels must be submitted no more than 30 days after they are printed [1].
The letter does not include a date for when the four-pack will be available to patients [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.